Manufacturing, Biologic Drugs

Sartorius Stedim Biotech to Equip Abzena Single-Use Manufacturing Sites

January 11, 2018

Sartorius Stedim Biotech will equip Abzena’s contract development and manufacturing facilities in Bristol, PA, and San Diego, CA, with single-use equipment and scale-up technologies.

Pfizer and Sangamo Partner on Gene Therapy for Lou Gehrig's Disease

January 05, 2018

The companies aim to develop a potential zinc finger protein transcription factor-based gene therapy for treating Lou Gehrig’s disease.

Wuxi Griffin Opens a New Aseptic Fill Finish Facility

January 04, 2018

The contract manufacturing company has completed construction on a new aseptic fill/finish facility in Wuxi, China.

Selecting and Installing Peristaltic Pump Tubing

January 02, 2018

Proper selection and installation optimizes fluid system performance.

FDA Approves Spark Therapeutics’ Gene Therapy for Inherited Vision Loss

December 20, 2017

FDA has approved a new gene therapy for treating patients born with a rare, inherited vision loss.

MilliporeSigma to Offer End-to-End MAb Manufacturing Using the iCON Platform

December 20, 2017

MilliporeSigma will collaborate with IPS and G-CON to offer end-to-end, turnkey, modular MAb manufacturing.

BioTek Adds “OnDemand” Mode to BioSpa Software

December 19, 2017

BioTek Instruments has released a second edition of its BioSpa software that now offers users a simplified but effective interface for kinetic imaging or detection workflows.

Sanofi and Alnylam Seek EMA Approval for RNAi Therapeutic

December 19, 2017

Sanofi Genzyme and its partner, Alnylam Pharmaceuticals, have filed a marketing authorization application with EMA for an investigational RNAi therapeutic for treating a genetic-based disease.

TxCell Completes CAR-Treg Manufacturing Process Development

December 19, 2017

The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.

FDA Approves Pfizer Biosimilar to J&J’s Remicade

December 14, 2017

FDA has approved a Pfizer biosimilar to J&J’s top-selling anti-inflammatory biologic, Remicade.